High serum vascular endothelial growth factor level is an adverse prognostic factor for high‐risk diffuse large <scp>B</scp>‐cell lymphoma patients treated with dose‐dense chemoimmunotherapy

Riihijärvi, Sari; Nurmi, Heidi; Holte, Harald; Björkholm, Magnus; Fluge, Øystein; Pedersen, Lars Møller; Rydström, Karin; Eriksson, Mikael; Leppä, Sirpa

doi:10.1111/ejh.12005

Cited by 13 publications

(15 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results, as well as those of others [31,35], showed that high serum VEGF levels were associated with advanced Ann Arbor stage, high IPI and the presence of B symptoms, which all somehow represent a measure of tumor burden. These results are in concordance with data showing that VEGF signaling is coupled to growth of lymphoma tissue [36].…”

Section: Discussionsupporting

confidence: 88%

“…Several study groups have found that elevated serum VEGF is associated with an unfavorable outcome and a poor prognosis in DLBCL, but all of these studies were performed before the rituximab era [13,15,16]. Recently, Riihijärvi et al [35] demonstrated that a high serum VEGF level is an adverse prognostic factor for patients with high-risk DLBCL treated with dose-dense chemoimmunotherapy. They confirmed the impact of serum VEGF levels on progression-free survival in different IPI subgroups and especially in patients with the nongerminal center subtype of DLBCL.…”

Section: Discussionmentioning

confidence: 99%

“…They confirmed the impact of serum VEGF levels on progression-free survival in different IPI subgroups and especially in patients with the nongerminal center subtype of DLBCL. However, the authors did not observe a corresponding prognostic effect of serum VEGF levels on OS [35]. …”

Section: Discussionmentioning

confidence: 99%

“…An abnormal vessel structure in the tumor locus, which may be a result of VEGF activity, can lead to lower drug delivery [38]. Finally, there is some evidence that high VEGF concentrations play a role in immune evasion of lymphoma cells [35,39]. Taken together, these findings indicate a significant tumor-promoting role for VEGF in DLBCL, and serum levels of this proangiogenic cytokine may thus be an important biomarker of tumor aggressiveness and act as a predictor of survival.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Concurrent Elevations of VEGF, Osteopontin and MCP-1 Serum Levels Are Independent Predictors of Survival in Patients with Diffuse Large B-Cell Lymphoma

Duletić-Načinović

Gačić²,

Valković³

et al. 2016

Acta Haematol

View full text Add to dashboard Cite

Background: Diffuse large B-cell lymphomas (DLBCL) are heterogeneous diseases, and the identification of additional DLBCL risk factors is especially important. Methods: In this pilot study, we determined pretreatment serum levels of vascular endothelial growth factor (VEGF), osteopontin (OPN) and macrophage chemotactic protein-1 (MCP-1) in 67 newly diagnosed DLBCL patients before treatment with standard chemoimmunotherapy and in 30 healthy persons. Results: Serum levels of all three cytokines were significantly elevated in untreated patients compared to controls. VEGF and OPN concentrations were higher in patients with advanced Ann Arbor stage, B symptoms, Eastern Cooperative Oncology Group score ≥2, International Prognostic Index (IPI) ≥3 and partial/no remission. A high MCP-1 level was associated with advanced stage, increased IPI and bone marrow infiltration. In univariate analysis, elevated OPN and VEGF, and concurrent elevation of all three biomarkers, were identified as significant predictors of poor survival. Multivariate Cox analysis revealed that elevated OPN combined with elevated VEGF levels was one of the best parameter subsets predicting poorest survival. Conclusion: According to our preliminary results, serum levels of VEGF and OPN before treatment predict response to therapy and survival after chemoimmunotherapy, and may help to further stratify DLBCL patients into risk groups.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Concurrent Elevations of VEGF, Osteopontin and MCP-1 Serum Levels Are Independent Predictors of Survival in Patients with Diffuse Large B-Cell Lymphoma

Duletić-Načinović

Gačić²,

Valković³

et al. 2016

Acta Haematol

View full text Add to dashboard Cite

show abstract

“…Increased VEGF activity has been associated with early recurrence in patients with cancer including GBM [10-12]. VEGF can be measured in biofluids such as urine, serum or plasma [13-15].…”

Section: Introductionmentioning

confidence: 99%

Predictive value of tumor recurrence using urinary vascular endothelial factor levels in patients receiving radiation therapy for Glioblastoma Multiforme (GBM)

et al. 2013

View full text Add to dashboard Cite

BackgroundGlioblastoma Multiforme (GBM) is the most common primary malignant tumor of the central nervous system. Standard of care includes maximal resection followed by chemoradiotherapy. Tumors need adequate perfusion and neovascularization to maintain oxygenation and for removal of wastes. Vascular endothelial growth factor (VEGF) is a well characterized pro-angiogenic factor. We hypothesized that the increases in urinary VEGF levels would occur early in the course of tumor recurrence or progression. We examine the feasibility of collecting and analyzing urinary VEGF levels in a prospective, multi-institutional trial (Radiation Therapy Oncology Group, RTOG, 0611) as well as the role of VEGF as a marker of tumor recurrence.MethodWe evaluated VEGF levels in urine specimens collected post-operatively, at the conclusion of radiation therapy (RT) and one month following RT. Urinary VEGF levels were correlated with tumor progression at one year. VEGF levels were measured by enzyme-linked immunosorbant assay in urine specimens and normalized to urinary creatinine levels. Sample size was determined based on a 50% 1-year recurrence rate. With a sensitivity and specificity of 80%, the expected 95% confidence interval was (0.69, 0.91) with 100 patients. A failure was defined as documented disease progression, recurrence or death before one year.Results202 patients were enrolled between February-2006 and October-2007. Four patients were ineligible as they did not receive RT. Of the remaining 198 patients, 128 had all three samples collected. In this group, 35 patients (27.3%) did not progress, 89 (69.5%) had progression and 4 (3.1%) died without evidence of progression. Median VEGF levels at baseline were 52.9 pg/mg Cr (range 0.2- 15,034.4); on the last day of RT, 56.6 (range 0–2,377.1); and at one month follow-up, 70.0 (range 0.1-1813.2). In patients without progression at 1-year, both baseline VEGF level and end of RT VEGF level were lower than those of patients who progressed: 40.3 (range 0.2-350.8) vs. 59.7 (range 1.3-15,034.4) and 41.8 (range 0–356.8) vs. 69.7 (range 0–2,377.1), respectively. This did not reach statistical significance. Comparison of the change in VEGF levels between the end of RT and one month following RT, demonstrated no significant difference in the proportions of progressors or non-progressors at 1-year for either the VEGF increased or VEGF decreased groups.ConclusionUrine can be collected and analyzed in a prospective, multi-institutional trial. In this study of patients with GBM a change in urinary VEGF levels between the last day of RT and the one month following RT did not predict for tumor progression by one year.

show abstract

B-cell non-Hodgkin lymphoma: importance of angiogenesis and antiangiogenic therapy

Jiang

2020

Angiogenesis

View full text Add to dashboard Cite

High serum vascular endothelial growth factor level is an adverse prognostic factor for high‐risk diffuse large B‐cell lymphoma patients treated with dose‐dense chemoimmunotherapy

Abstract: Pretreatment s-VEGF level is a predictor of PFS after chemoimmunotherapy and may help to further stratify high-risk DLBCL patients into low- and high-risk groups.

Cited by 13 publications

References 42 publications

Concurrent Elevations of VEGF, Osteopontin and MCP-1 Serum Levels Are Independent Predictors of Survival in Patients with Diffuse Large B-Cell Lymphoma

Concurrent Elevations of VEGF, Osteopontin and MCP-1 Serum Levels Are Independent Predictors of Survival in Patients with Diffuse Large B-Cell Lymphoma

Predictive value of tumor recurrence using urinary vascular endothelial factor levels in patients receiving radiation therapy for Glioblastoma Multiforme (GBM)

B-cell non-Hodgkin lymphoma: importance of angiogenesis and antiangiogenic therapy

Contact Info

Product

Resources

About